Tranzyme Pharma discovered and developed novel, mechanism-based therapeutics based on its proprietary small molecule macrocyclic template chemistry (MATCH™) technology. MATCH enables the rapid construct of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. Tranzyme Pharma merged with Ocera Therapeutics in 2013.